loader
Please Wait
Applying Filters...

Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Ferrous Succinate, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Ferrous Succinate

    APIs // Active Pharmaceutical Ingredients

    PRICE INFORMATION

    MARKET PLACE

    PharmaCompass

    Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.

    One Pharma aims to be one of the leading generic companies in Europe.

    2D Structure
    1. Also known as: Iron succinate, 10030-90-7, Iron(ii) succinate, Butanedioate;iron(2+), Butanedioic acid, iron(2+) salt (1:1), 818zyk7n91
    Molecular Formula
    C4H4FeO4
    Molecular Weight
    171.92  g/mol
    InChI Key
    MDXRFOWKIZPNTA-UHFFFAOYSA-L
    FDA UNII
    818ZYK7N91
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    butanedioate;iron(2+)
    2.1.2 InChI
    InChI=1S/C4H6O4.Fe/c5-3(6)1-2-4(7)8;/h1-2H2,(H,5,6)(H,7,8);/q;+2/p-2
    2.1.3 InChI Key
    MDXRFOWKIZPNTA-UHFFFAOYSA-L
    2.1.4 Canonical SMILES
    C(CC(=O)[O-])C(=O)[O-].[Fe+2]
    2.2 Other Identifiers
    2.2.1 UNII
    818ZYK7N91
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Butanedioic Acid, Iron (+2) Salt

    2. Ferromyn

    3. Ferrosuccinate

    2.3.2 Depositor-Supplied Synonyms

    1. Iron Succinate

    2. 10030-90-7

    3. Iron(ii) Succinate

    4. Butanedioate;iron(2+)

    5. Butanedioic Acid, Iron(2+) Salt (1:1)

    6. 818zyk7n91

    7. Succinic Acid Iron(ii) Salt;succinic Acid Iron(ii) Salt

    8. Unii-818zyk7n91

    9. Ferrlecit 2

    10. Einecs 233-082-3

    11. Ferplex (tn)

    12. Ferromyn

    13. Succinic Acid Iron(ii) Salt

    14. Schembl275423

    15. Ferrous Succinate [mi]

    16. Iron Succinate (fe(o4c4h4))

    17. Ferrous Succinate [mart.]

    18. Ferrous Succinate [who-dd]

    19. Db14489

    20. D08015

    21. Succinic Acid, Iron(2+) Salt (1:1)

    22. Q27269230

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 171.92 g/mol
    Molecular Formula C4H4FeO4
    Hydrogen Bond Donor Count0
    Hydrogen Bond Acceptor Count4
    Rotatable Bond Count1
    Exact Mass171.945894 g/mol
    Monoisotopic Mass171.945894 g/mol
    Topological Polar Surface Area80.3 Ų
    Heavy Atom Count9
    Formal Charge0
    Complexity81.6
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Indication

    Used in preventing and treating iron-deficiency anemia.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    The major activity of supplemental iron is in the prevention and treatment of iron deficiency anemia. Iron has putative immune-enhancing, anticarcinogenic and cognition-enhancing activities.

    5.2 MeSH Pharmacological Classification

    Hematinics

    Agents which improve the quality of the blood, increasing the hemoglobin level and the number of erythrocytes. They are used in the treatment of anemias. (See all compounds classified as Hematinics.)

    5.3 ATC Code

    B - Blood and blood forming organs

    B03 - Antianemic preparations

    B03A - Iron preparations

    B03AA - Iron bivalent, oral preparations

    B03AA06 - Ferrous succinate

    5.4 Absorption, Distribution and Excretion

    Absorption

    The efficiency of absorption depends on the salt form, the amount administered, the dosing regimen and the size of iron stores. Subjects with normal iron stores absorb 10% to 35% of an iron dose. Those who are iron deficient may absorb up to 95% of an iron dose.

    5.5 Mechanism of Action

    Iron is necessary for the production of hemoglobin. Iron-deficiency can lead to decreased production of hemoglobin and a microcytic, hypochromic anemia.

    Post Enquiry
    POST ENQUIRY